Tumor Hypoxia and Targeted Gene Therapy

International Review of Cytology

Volumn 257, Issue , 2007, Pages 181-212

  Greco, Olga ^a   Scott, Simon ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Bioreductive drugs; CArG elements; Chemotherapy; Cre loxP; HIF; HRE; Radiation; Suicide gene therapy

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; ONCOLYTIC VIRUS;

CANCER CHEMOTHERAPY; CANCER GENE THERAPY; EUKARYOTIC CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HYPOXIA; PRIORITY JOURNAL; PROKARYOTIC CELL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CELL HYPOXIA; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS;

EID: 33846581569     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(07)57005-1     Document Type: Review

References (186)

1. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., and Semenza G.L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61 (2001) 2911-2916
2. Akakura N., Kobayashi M., Horiuchi I., Suzuki A., Wang J., Chen J., Niizeki H., Kawamura K., Hosokawa M., and Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61 (2001) 6548-6554
3. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 (2003) 46-54
4. Andreesen R., Henneman B., and Krause S.W. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives. J. Leukoc. Biol. 64 (1998) 419-426
5. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., and Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93 (1996) 12969-12973
6. Arnesen T., Anderson D., Baldersheim C., Lanotte M., Varhaug J.E., and Lillehaug J.R. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 386 (2005) 433-443
7. Bae S.H., Jeong J.W., Park J.A., Kim S.H., Bae M.K., Choi S.J., and Kim K.W. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324 (2004) 394-400
8. Barbe S., Van Mellaert L., Theys J., Geukens N., Lammertyn E., Lambin P., and Anne J. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol. Lett. 246 (2005) 67-73
9. Becker A., Hansgen G., Bloching M., Weigel C., Lautenschlager C., and Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 35-41
10. Bilton R., Mazure N., Trottier E., Hattab M., Dery M.A., Richard D.E., Pouyssegur J., and Brahimi-Horn M.C. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J. Biol. Chem. 280 (2005) 31132-31140
11. Binley K., Askham Z., Martin L., Spearman H., Day D., Kingsman S., and Naylor S. Hypoxia-mediated tumour targeting. Gene Ther. 10 (2003) 540-549
12. Birner P., Gatterbauer B., Oberhuber G., Schindl M., Rossler K., Prodinger A., Budka H., and Hainfellner J.A. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
13. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60 (2000) 4693-4696
14. Brizel D.M., Schroeder T., Scher R.L., Walenta S., Clough R.W., Dewhirst M.W., and Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 349-353
15. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., and Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56 (1996) 941-943
16. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 285-289
17. Brown J.M. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br. J. Radiol. 52 (1979) 650-656
18. Brown L.M., Cowen R.L., Debray C., Eustace A., Erler J.T., Sheppard F.C., Parker C.A., Stratford I.J., and Williams K.J. Reversing Hypoxic Cell Chemoresistance In Vitro Using Genetic And Small Molecule Approaches Targeting Hypoxia Inducible Factor-1. Mol. Pharmacol. 69 (2005) 411-418
19. Burke B. Macrophages as novel cellular vehicles for gene therapy. Expert Opin. Biol. The.r 3 (2003) 919-924
20. Burke B., Tang N., Corke K.P., Tazzyman D., Ameri K., Wells M., and Lewis C.E. Expression of HIF-1α by human macrophages: Implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol. 196 (2002) 204-212
21. Burton J.L., Wells J.M., Corke K.P., Maitland N., Hambdy F.C., and Lewis C.E. Macrophages accumulate in avascular, hypoxic areas of prostate tumours: Implications for the targeted therapeutic gene delivery to such sites. J. Pathol. 192 (2000) 8A
22. Carey R.W., Holland J.F., Whang H.Y., Neter E., and Bryant B. Clostridial oncolysis in man. Eur. J. Cancer 3 (1967) 37-46
23. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
24. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 20 (2000) 402-415
25. Chadderton N., Cowen R.L., Sheppard F.C., Robinson S., Greco O., Scott S.D., Stratford I.J., Patterson A.V., and Williams K.J. Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 213-222
26. Chaplin D.J., Acker B., and Olive P.L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int. J. Radiat. Oncol. Biol. Phys. 16 (1989) 1131-1135
27. Chaplin D.J., Horsman M.R., Trotter M.J., and Siemann D.W. Therapeutic significance of microenvironmental factors. In: Molls M., and Vaupel P. (Eds). "Therapeutic significance of microenvironmental factors" (1998), Springer-Verlag, Berlin 133-143
28. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res. 47 (1987) 597-601
29. Cho W.K., Seong Y.R., Lee Y.H., Kim M.J., Hwang K.S., Yoo J., Choi S., Jung C.R., and Im D.S. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther. 10 (2004) 938-949
30. Choo H.-J., Youn S.-W., Cheon S.-I., Kim T.-Y., Hur J., Zhang S.-Y., Lee S.P., Park K.-W., Lee M.-M., Choi Y.-S., Park Y.-B., and Kim H.-S. Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrin-linked kinase. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1154-1160
31. Connor J.H., Naczki C., Koumenis C., and Lyles D.S. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J. Virol. 78 (2004) 8960-8970
32. Cowen R.L., Williams K.J., Chinje E.C., Jaffar M., Sheppard F.C., Telfer B.A., Wind N.S., and Stratford I.J. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Res. 64 (2004) 1396-1402
33. Craighead P.S., Pearcey R., and Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 791-795
34. Cuevas Y., Hernandez-Alcoceba R., Aragones J., Naranjo-Suarez S., Castellanos M.C., Esteban M.A., Martin-Puig S., Landazuri M.O., and del Peso L. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res. 63 (2003) 6877-6884
35. Dai S., Huang M.L., Hsu C.Y., and Chao K.S. Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 1027-1036
36. De S.K., Venkateshan C.N., Seth P., Gadjusek D.C., and Gibbs C.J. Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect of Nef on down-modulation of Fcgamma receptors and expression of monokines. Blood 91 (1998) 2108-2117
37. Durand R.E., and Raleigh J.A. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58 (1998) 3547-3550
38. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., Miller C., Demonacos C., Stratford I.J., and Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24 (2004) 2875-2889
39. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
40. Fisher T.S., Etages S.D., Hayes L., Crimin K., and Li B. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem. 280 (2005) 17749-17757
41. Fox M.E., Lemmon M.J., Mauchline M.L., Davis T.O., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 3 (1996) 173-178
42. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62 (2002) 4968-4976
43. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63 (2003) 7497-7506
44. Fu G.F., Li X., Hou Y.Y., Fan Y.R., Liu W.H., and Xu G.X. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 12 (2005) 133-140
45. Fuller J., Feldmann H.J., Molls M., and Sack H. Studies on oxygen partial pressure in tumor tissue under radiotherapy and thermoradiotherapy. Strahlenther. Onkol. 170 (1994) 453-460
46. Fyles A., Milosevic M., Hedley D., Pintilie M., Levin W., Manchul L., and Hill R.P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20 (2002) 680-687
47. Giatromanolaki A., Koukourakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K.C., and Harris A.L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61 (2001) 7992-7998
48. Grau C., and Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13 (1988) 301-309
49. Greco O., and Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J. Cell. Physiol. 187 (2001) 22-36
50. Greco O., Marples B., Dachs G.U., Williams K.J., Patterson A.V., and Scott S.D. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 9 (2002) 1403-1411
51. Greco O., Marples B., Joiner M.C., and Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J. Cell. Physiol. 197 (2003) 312-325
52. Greco O., Patterson A.V., and Dachs G.U. Can gene therapy overcome the problem of hypoxia in radiotherapy?. J. Radiat. Res. (Tokyo) 41 (2000) 201-212
53. Greco O., Joiner M.C., Doleh A., Powell A.D., Hillman G.G., and Scott S.D. Hypoxia- and radiation-activated Cre/loxP "molecular switch" vectors for gene therapy of cancer. Gene Ther. 13 (2006) 206-215
54. Griffiths J.R. Are cancer cells acidic?. Br. J. Cancer 64 (1991) 425-427
55. Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., and Naylor S. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7 (2000) 255-262
56. Grimshaw M.J., Wilson J.L., and Balkwill F.R. Endothelin-2 is a macrophage chemoattractant: Implications for macrophage distribution in tumors. Eur. J. Immunol. 32 (2002) 2393-2400
57. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7 (1998) 205-213
58. Gunaratnam L., Morley M., Franovic A., de Paulsen N., Mekhail K., Parolin D.A., Nakamura E., Lorimer I.A., and Lee S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278 (2003) 44966-44974
59. Haddada H., Lopez M., Martinache C., Ragot T., Abina M.A., and Perricaudet M. Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 195 (1993) 1174-1183
60. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
61. Haugland H.K., Vukovic V., Pintilie M., Fyles A.W., Milosevic M., Hill R.P., and Hedley D.W. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: Correlation with tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 854-861
62. Hernandez-Alcoceba R., Pihalja M., Nunez G., and Clarke M.F. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 8 (2001) 298-307
63. Hernandez-Alcoceba R., Pihalja M., Qian D., and Clarke M.F. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther. 13 (2002) 1737-1750
64. Hill S.A., Pigott K.H., Saunders M.I., Powell M.E., Arnold S., Obeid A., Ward G., Leahy M., Hoskin P.J., and Chaplin D.J. Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br. J. Cancer Suppl. 27 (1996) S260-S263
65. Höpfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., Stratford I.J., Gassmann M., et al. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62 (2002) 2962-2970
66. Huang L.E., Arany Z., Livingston D.M., and Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J. Biol. Chem. 271 (1996) 32253-32259
67. Hughes C.S., Shen J.W., and Subjeck J.R. Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res. 49 (1989) 4452-4454
68. Ido A., Uto H., Moriuchi A., Nagata K., Onaga Y., Onaga M., Hori T., Hirono S., Hayashi K., Tamaoki T., and Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 61 (2001) 3016-3021
69. Ingram N., and Porter C.D. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther. 12 (2005) 1058-1069
70. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., and Kaelin Jr. W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292 (2001) 464-468
71. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
72. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
73. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57 (1997) 5328-5335
74. Kelly P.M., Davison R.S., Bliss E., and McGee J.O. Macrophages in human breast disease: A quantitative immunohistochemical study. Br. J. Cancer 57 (1988) 174-177
75. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., and Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56 (1996) 5522-5528
76. Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53 (1993) 3992-3997
77. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C., and Harris A.L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1192-1202
78. Koukourakis M.I., Giatromanolaki A., Skarlatos J., Corti L., Blandamura S., Piazza M., Gatter K.C., and Harris A.L. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61 (2001) 1830-1832
79. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6 (2000) 1335-1340
80. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
81. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
82. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23 (2004) 293-310
83. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., and Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56 (1996) 4625-4629
84. Leek R.D., Landers R.J., Underwood J.C., Harris A.L., and Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltrationin invasive carcinoma of the breast. Br. J. Cancer 79 (1999) 991-995
85. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997) 791-796
86. Lewis J.S., Landers R.J., Underwood J.C., Harris A.L., and Lewis C.E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192 (2000) 150-158
87. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., and Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 (2005) 7249-7258
88. Li X., Fu G.F., Fan Y.R., Liu W.H., Liu X.J., Wang J.J., and Xu G.X. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10 (2003) 105-111
89. Li Y.M., Zhou B.P., Deng J., Pan Y., Hay N., and Hung M.C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res. 65 (2005) 3257-3263
90. Lipnik K., Greco O., Scott S., Knappm E., Mayrhofer E., Rosenfellner D., Gunzburg W.H., Salmons B., and Hohenadl C. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology 349 (2006) 121-133
91. Lissbrant I.F., Stattin P., Wikstrom P., Damber J.E., Egevad L., and Bergh A. Tumour associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival. Int. J. Oncol. 17 (2000) 445-451
92. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9 (2002) 291-296
93. Liu Y., Santin A.D., Mane M., Chiriva-Internati M., Parham G.P., Ravaggi A., and Hermonat P.L. Transduction and utility of the granulocyte macrophage colony stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J. Interferon Cytokine Res. 20 (2000) 21-30
94. Lorence R.M., Pecora A.L., Major P.P., Hotte S.J., Laurie S.A., Roberts M.S., Groene W.S., and Bamat M.K. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5 (2003) 618-624
95. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
96. Malmgren R.A., and Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumours following intravenous spore administration. Cancer Res. 15 (1955) 473-478
97. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
98. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., and Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (1997) 8104-8109
99. Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA 90 (1993) 2423-2427
100. Mazure N.M., Brahimi-Horn M.C., Berta M.A., Benizri E., Bilton R.L., Dayan F., Ginouves A., Berra E., and Pouyssegur J. HIF-1: Master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem. Pharmacol. 68 (2004) 971-980
101. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2 (2003) S157-S160
102. Mei S., Theys J., Landuyt W., Anne J., and Lambin P. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium. Anticancer Res. 22 (2002) 3261-3266
103. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
104. Mineta T., Rabkin S.D., and Martuza R.L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54 (1994) 3963-3966
105. Miyake K., Suzuki N., Matsuoka H., Tohyama T., and Shimada T. Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells. Hum. Gene Ther. 9 (1998) 467-475
106. Mizuno T., Nagao M., Yamada Y., Narikiyo M., Ueno M., Miyagishi M., Taira K., and Nakajima Y. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther. 13 (2005) 131-140
107. Modlich U., Pugh C.W., and Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 7 (2000) 896-902
108. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
109. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
110. Nakanishi K., Hiroi S., Tominaga S., Aida S., Kasamatsu H., Matsuyama S., Matsuyama T., and Kawai T. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin. Cancer Res. 11 (2005) 2583-2590
111. Negus R.P., Stamp G.W., Hadley J., and Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150 (1997) 1723-1734
112. Negus R.P., Turner L., Burke F., and Balkwill F.R. Hypoxia down-regulates MCP-1 expression: Implications for macrophage distribution in tumours. J. Leukoc. Biol. 63 (1998) 758-765
113. Nemunaitis J., Cunningham C., Senzer N., Kuhn J., Cramm J., Litz C., Cavagnolo R., Cahill A., Clairmont C., and Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10 (2003) 737-744
114. Nuyts S., Theys J., Landuyt W., van Mellaert L., Lambin P., and Anne J. Increasing specificity of anti-tumor therapy: Cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res. 21 (2001) 857-861
115. Nuyts S., Van Mellaert L., Theys J., Landuyt W., Bosmans E., Anne J., and Lambin P. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 8 (2001) 1197-1201
116. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
117. Ogawa T., Takayama K., Takakura N., Kitano S., and Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 9 (2002) 633-640
118. Ogura M., Shibata T., Yi J., Liu J., Qu R., Harada H., and Hiraoka M. A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Sci. 96 (2005) 288-294
119. Ozawa T., Hu J.L., Hu L.J., Kong E.L., Bollen A.W., Lamborn K.R., and Deen D.F. Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Ther. 12 (2005) 449-455
120. Park S.Y., Billiar T.R., and Seol D.W. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem. Biophys. Res. Commun. 291 (2002) 150-153
121. Parveen Z., Krupetsky A., Engelstadter M., Cichutek K., Pomeranntz R.J., and Dornburg R. Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells. Nat. Biotechnol. 18 (2000) 623-629
122. Pastorino S., Massazza S., Cilli M., Varesio L., and Bosco M.C. Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Ther. 8 (2001) 431-441
123. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Strafford I. Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer 76 (1997) 1338-1347
124. Patterson A.V., Saunders M.P., and Greco O. Prodrugs in genetic chemoradiotherapy. Curr. Pharm. Des. 9 (2003) 2131-2154
125. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., van der Kogel A.J., Wolf C.R., and Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 9 (2002) 946-954
126. Paul S., Snary D., Hoebecke J., Allen D., Balloul J.M., Bizouarne N., Dott K., Geist M., Hilgers J., Kieny M.P., Burchell J., Taylor-Papadimitriou J., et al. Targeted macrophage toxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. Hum. Gene Ther. 11 (2000) 1417-1428
127. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57 (1997) 4537-4544
128. Pin R.H., Reinblatt M., Bowers W.J., Federoff H.J., and Fong Y. Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J. Gastrointest. Surg. 8 (2004) 812-822 discussion 822-823
129. Pin R.H., Reinblatt M., and Fong Y. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. Surgery 136 (2004) 199-204
130. Pipiya T., Sauthoff H., Huang Y.Q., Chang B., Cheng J., Heitner S., Chen S., Rom W.N., and Hay J.G. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther. 12 (2005) 911-917
131. Pitson G., Fyles A., Milosevic M., Wylie J., Pintilie M., and Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 699-703
132. Post D.E., and Van Meir E.G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22 (2003) 2065-2072
133. Post D.E., Devi N.S., Li Z., Brat D.J., Kaur B., Nicholson A., Olson J.J., Zhang Z., and Van Meir E.G. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin. Cancer Res. 10 (2004) 8603-8612
134. Post D.E., Fulci G., Chiocca E.A., and Van Meir E.G. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. 4 (2004) 41-51
135. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., and Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem. 272 (1997) 11205-11214
136. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., Ballenger C.A., Weissler M.C., Fowler Jr. W.C., Novotny D.B., and Varia M.A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58 (1998) 3765-3768
137. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 (2000) 34-44
138. Reinblatt M., Pin R.H., Federoff H.J., and Fong Y. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann. Surg. 239 (2004) 892-899 discussion 899-902
139. Rischin D., Peters L., Hicks R., Hughes P., Fisher R., Hart R., Sexton M., D'Costa I., and von Roemeling R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19 (2001) 535-542
140. Rofstad E.K., Sundfor K., Lyng H., and Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 83 (2000) 354-359
141. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
142. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
143. Sanna K., and Rofstad E.K. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int. J. Cancer 58 (1994) 258-262
144. Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., and Stratford I.J. NADPH: Cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br. J. Cancer 82 (2000) 651-656
145. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., Jakesz R., Kubista E., Birner P., and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8 (2002) 1831-1837
146. Schneider S.D., Rusconi S., Seger R.A., and Josle J.P. Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: Ex vivo correction od deficient respiratory burst. Gene Ther. 4 (1997) 524-532
147. Schroers R., Sinha I., Segall H., Schmidt-Wolf I.G., Rooney C.M., Brenner M.K., Sutton R.E., and Chen S.Y. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 1 (2000) 171-179
148. Scott S.D., and Greco O. Radiation and hypoxia inducible gene therapy systems. Cancer Metast. Rev. 23 (2004) 269-276
149. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
150. Shen B.H., and Hermiston T.W. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 12 (2005) 902-910
151. Shen J., Hughes C., Chao C., Cai J., Bartels C., Gessner T., and Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. USA 84 (1987) 3278-3282
152. Simoes S., Slepushkin V., Pretzer E., Dazin P., Gaspar R., Pedroso de Lima M.C., and Duzgunes N. Transfection of human macrophages by lipoplexes via the combined use of transferrin and pH-sensitive peptides. J. Leukoc. Biol. 65 (1999) 270-279
153. Smith K., Gunaratnam L., Morley M., Franovic A., Mekhail K., and Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 65 (2005) 5221-5230
154. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., and Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61 (2001) 6669-6673
155. Stratford I.J., and Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des. 13 (1998) 519-528
156. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., and Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 (2001) 638-645
157. Sun X., Kanwar J.R., Leung E., Vale M., and Krissansen G.W. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha. Gene Ther. 10 (2003) 2081-2089
158. Sun X., Liu M., Wei Y., Liu F., Zhi X., Xu R., and Krissansen G.W. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther. 13 (2006) 428-435
159. Sundfor K., Lyng H., and Rofstad E.K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer 78 (1998) 822-827
160. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L., and O'Byrne K.J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 111 (2004) 43-50
161. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
162. Tang R., Beuvon F., Ojeda M., Mosseri V., Pouillart P., and Scholl S. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?. J. Cell. Biochem. 50 (1992) 350-356
163. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41 (1981) 73-81
164. Theys J., Landuyt W., Nuyts S., Van Mellaert L., Bosmans E., Rijnders A., Van Den Bogaert W., van Oosterom A., Anne J., and Lambin P. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol. Med. Microbiol. 30 (2001) 37-41
165. Theys J., Landuyt W., Nuyts S., Van Mellaert L., van Oosterom A., Lambin P., and Anne J. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 8 (2001) 294-297
166. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
167. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 5 (2005) 423-435
168. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., and Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6 (2000) 3282-3289
169. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., and Wenger R.H. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22 (2003) 3213-3220
170. Vaupel P., and Hockel M. Oxygenation of human tumours. In: Molls M., and Vaupel P. (Eds). "Therapeutic Significance of Microenvironmental Factors" (1998), Springer-Verlag, Berlin 133-143
171. Wang D., Ruan H., Hu L., Lamborn K.R., Kong E.L., Rehemtulla A., and Deen D.F. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther. 12 (2005) 276-283
172. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
173. Wei J., Blum S., Unger M., Jarmy G., Lamparter M., Geishauser A., Vlastos G.A., Chan G., Fischer K.D., Rattat D., Debatin K.M., Hatzopoulos A.K., et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 5 (2004) 477-488
174. Wenger R.H., and Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378 (1997) 609-616
175. Wiener C.M., Booth G., and Semenza G.L. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 225 (1996) 485-488
176. Wiesener M.S., Turley H., Allen W.E., Willam C., Eckardt K.U., Talks K.L., Wood S.M., Gatter K.C., Harris A.L., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92 (1998) 2260-2268
177. Williams K.J., Telfer B.A., Xenaki D., Sheridan M.R., Desbaillets I., Peters H.J., Honess D., Harris A.L., Dachs G.U., van der Kogel A., and Stratford I.J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75 (2005) 89-98
178. Wouters B.G., and Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147 (1997) 541-550
179. Yang L., Cao Z., Li F., Post D.E., Van Meir E.G., Zhong H., and Wood W.C. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 11 (2004) 1215-1223
180. Yazawa K., Fujimori M., Amano J., Kano Y., and Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther. 7 (2000) 269-274
181. Yazawa K., Fujimori M., Nakamura T., Sasaki T., Amano J., Kano Y., and Taniguchi S. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res. Treat. 66 (2001) 165-170
182. Yew P.R., and Berk A.J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357 (1992) 82-85
183. Zhang X., Kon T., Wang H., Li F., Huang Q., Rabbani Z.N., Kirkpatrick J.P., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 64 (2004) 8139-8142
184. Zhong H., Agani F., Baccala A.A., Laughner E., Rioseco-Camacho N., Isaacs W.B., Simons J.W., and Semenza G.L. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 58 (1998) 5280-5284
185. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (2000) 1541-1545
186. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835